Get started
Author

Kathryn A. Arrambide

Observed names: K. Arrambide, Kathryn Arrambide
ORCID: 0000-0001-6252-7252
Observed ORCID: 0000-0001-6252-7252
OpenAlex ID: A5020169144
ZEBRA: A Multicenter Phase II Study of Pembrolizumab in Patients with Advanced Small-Bowel Adenocarcinoma
2021 · Katrina S. Pedersen, Nathan R. Foster, et al. · Clinical Cancer Research · 64
Loss of absorptive capacity for sodium chloride as a cause of diarrhea following partial ileal and right colon resection
1989 · Kathryn A. Arrambide, Carol A. Santa Ana, et al. · Digestive Diseases and Sciences · 37
ZEBRA: an ACCRU/IRCI multicenter phase 2 study of pembrolizumab in patients with advanced small bowel adenocarcinoma (SBA)
2019 · K. Pedersen, N. Foster, et al. · Annals of Oncology · 10
PDF
Data from ZEBRA: A Multicenter Phase II Study of Pembrolizumab in Patients with Advanced Small-Bowel Adenocarcinoma
2023 · Katrina S. Pedersen, Nathan R. Foster, et al.
Supplementary Data from ZEBRA: A Multicenter Phase II Study of Pembrolizumab in Patients with Advanced Small-Bowel Adenocarcinoma
2023 · Katrina S. Pedersen, Nathan R. Foster, et al.
Supplementary Data from ZEBRA: A Multicenter Phase II Study of Pembrolizumab in Patients with Advanced Small-Bowel Adenocarcinoma
2023 · Katrina S. Pedersen, Nathan R. Foster, et al.
Data from ZEBRA: A Multicenter Phase II Study of Pembrolizumab in Patients with Advanced Small-Bowel Adenocarcinoma
2023 · Katrina S. Pedersen, Nathan R. Foster, et al.
ZEBRA: An IRCI/ACCRU (RU021502I) Multicenter Phase II Study of Pembrolizumab in Patients With Advanced Small Bowel Adenocarcinoma (SBA)
2020 · Katrina S. Pedersen, Nathan R. Foster, et al. · SSRN Electronic Journal
Works count: 9
Citation count: 111
H-index: 3
I10-index: 3
Year
Topic
Type